Table of Contents
Cardiovascular Psychiatry and Neurology
Volume 2012 (2012), Article ID 942981, 8 pages
http://dx.doi.org/10.1155/2012/942981
Research Article

Neurodegenerative Shielding by Curcumin and Its Derivatives on Brain Lesions Induced by 6-OHDA Model of Parkinson's Disease in Albino Wistar Rats

1Department of Pharmacology, Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), Pushp Vihar, Sector 3, M. B. Road, New Delhi 110017, India
2Innovative College of Pharmacy, Plot No. 6, Knowledge Park-II, Greater Noida, Gautam Buddha Nagar, Uttar Pradesh 201306, India

Received 21 May 2012; Revised 2 July 2012; Accepted 8 July 2012

Academic Editor: Gjumrakch Aliev

Copyright © 2012 Shyam Sunder Agrawal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. C. Herdman and B. B. Potter, Neural Grafting: Repairing the Brain and Spinal Cord, Government Printing Office. U.S. Congress, Office of Technology Assessment, Washington, DC, USA, 1990.
  2. H. Yuan, L. W. Liang, Z. J. Chen et al., “R-apomorphine protects against 6-hydroxydopamine-induced nigrostriatal damage in rat,” Neuroscience Bulletin, vol. 22, no. 6, pp. 331–338, 2006. View at Google Scholar · View at Scopus
  3. A. Schober, “Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP,” Cell and Tissue Research, vol. 318, no. 1, pp. 215–224, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. S. M. Papa and T. N. Chase, “Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys,” Annals of Neurology, vol. 39, no. 5, pp. 574–578, 1996. View at Google Scholar · View at Scopus
  5. M.-F. Chesselet and F. Richter, “Modelling of Parkinson's disease in mice,” The Lancet Neurology, vol. 10, no. 12, pp. 1108–1118, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. G. M. Cole, B. Teter, and S. A. Frautschy, “Neuroprotective effects of curcumin,” Advances in Experimental Medicine and Biology, vol. 595, pp. 197–212, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Hatcher, R. Planalp, J. Cho, F. M. Torti, and S. V. Torti, “Curcumin: from ancient medicine to current clinical trials,” Cellular and Molecular Life Sciences, vol. 65, no. 11, pp. 1631–1652, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. B. B. Aggarwal and B. Sung, “Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets,” Trends in Pharmacological Sciences, vol. 30, no. 2, pp. 85–94, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. H. H. Tonnesen, “Studies on curcumin and curcuminoids. XV. Catalytic effect of demethoxy- and bisdemethoxycurcumin on the peroxidation of linoleic acid by 15-lipoxygenase,” International Journal of Pharmaceutics, vol. 51, no. 2, pp. 179–181, 1989. View at Google Scholar · View at Scopus
  10. H. Inano, M. Onoda, N. Inafuku et al., “Potent preventive action of curcumin on radiation-induced initiation of mammary tumorigenesis in rats,” Carcinogenesis, vol. 21, no. 10, pp. 1835–1841, 2000. View at Google Scholar · View at Scopus
  11. M. A. Kelly, M. Rubinstein, T. J. Phillips et al., “Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations,” Journal of Neuroscience, vol. 18, no. 9, pp. 3470–3479, 1998. View at Google Scholar · View at Scopus
  12. J. R. Boissier and P. Simon, “Action of caffeine on the spontaneous motility of the mouse,” Archives Internationales de Pharmacodynamie et de Therapie, vol. 158, no. 1, pp. 212–221, 1965. View at Google Scholar · View at Scopus
  13. D. K. Pandey, R. Mahesh, A. A. kumar, V. S. Rao, M. Arjun, and R. Rajkumar, “A novel 5-HT2A receptor antagonist exhibits antidepressant-like effects in a battery of rodent behavioural assays: approaching early-onset antidepressants,” Pharmacology Biochemistry and Behavior, vol. 94, no. 3, pp. 363–373, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Paxinos and C. Watson, The Rat Brain Stereotaxic Coordinates, Academic Press, Sydney, Australia, 1981.
  15. A. K. Agrawal, R. E. Squibb, and S. C. Bondy, “The effects of acrylamide treatment upon the dopamine receptor,” Toxicology and Applied Pharmacology, vol. 58, no. 1, pp. 89–99, 1981. View at Google Scholar · View at Scopus
  16. H. Haikala, “Use of a novel type of rotating disc electrode and a flow cell with laminar flow pattern for the electrochemical detection of biogenic monoamines and their metabolites after Sephadex gel chromatographic purification and high-performance liquid chromatographic isolation from rat brain,” Journal of Neurochemistry, vol. 49, no. 4, pp. 1033–1041, 1987. View at Google Scholar · View at Scopus
  17. I. C. Kilpatrick, M. W. Jones, and O. T. Phillipson, “A semiautomated analysis method for catecholamines, indoleamines, and some prominent metabolites in microdissected regions of the nervous system: an isocratic HPLC technique employing coulometric detection and minimal sample preparation,” Journal of Neurochemistry, vol. 46, no. 6, pp. 1865–1876, 1986. View at Google Scholar · View at Scopus
  18. S. Mishra and K. Palanivelu, “The effect of curcumin (turmeric) on Alzheimer's disease: an overview,” Annals of Indian Academy of Neurology, vol. 11, no. 1, pp. 13–19, 2008. View at Google Scholar · View at Scopus
  19. T. Shingo, I. Date, H. Yoshida, and T. Ohmoto, “Neuroprotective and restorative effects of intrastriatal grafting of encapsulated GDNF-producing cells in a rat model of Parkinson's disease,” Journal of Neuroscience Research, vol. 69, no. 6, pp. 946–954, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Zecca, F. A. Zucca, H. Wilms, and D. Sulzer, “Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics,” Trends in Neurosciences, vol. 26, no. 11, pp. 578–580, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. K. A. Malkus, E. Tsika, and H. Ischiropoulos, “Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle,” Molecular Neurodegeneration, vol. 4, no. 1, article 24, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. B. J. Kelley and D. S. Knopman, “Alternative medicine and Alzheimer disease,” Neurologist, vol. 14, no. 5, pp. 299–306, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Yang, G. P. Lim, A. N. Begum et al., “Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo,” Journal of Biological Chemistry, vol. 280, no. 7, pp. 5892–5901, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Yodkeeree, W. Chaiwangyen, S. Garbisa, and P. Limtrakul, “Curcumin, demethoxycurcumin and bisdemethoxycurcumin differentially inhibit cancer cell invasion through the down-regulation of MMPs and uPA,” Journal of Nutritional Biochemistry, vol. 20, no. 2, pp. 87–95, 2009. View at Publisher · View at Google Scholar · View at Scopus